Next Biomedical Co.,Ltd. (KOSDAQ:389650)
South Korea
· Delayed Price · Currency is KRW 60,700
-3,000 (-4.71%)
At close: Apr 28, 2026
Next Biomedical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Operating Revenue | 16,477 | 9,543 | 4,882 | 2,795 | 2,267 | Upgrade
|
| Other Revenue | -0 | - | - | -0 | - | Upgrade
|
| Revenue | 16,477 | 9,543 | 4,882 | 2,795 | 2,267 | Upgrade
|
| Revenue Growth (YoY) | 72.67% | 95.46% | 74.67% | 23.28% | 0.29% | Upgrade
|
| Cost of Revenue | 5,028 | 3,787 | 2,813 | 2,618 | 2,998 | Upgrade
|
| Gross Profit | 11,449 | 5,755 | 2,069 | 177.49 | -731.09 | Upgrade
|
| Selling, General & Admin | 4,465 | 2,610 | 2,407 | 2,246 | 2,866 | Upgrade
|
| Research & Development | 7,581 | 6,622 | 4,783 | 3,579 | 3,245 | Upgrade
|
| Amortization of Goodwill & Intangibles | 11.96 | 22.71 | 31.02 | 34.25 | 31.6 | Upgrade
|
| Other Operating Expenses | 26.03 | 21.51 | 20.04 | 19.29 | 18.39 | Upgrade
|
| Operating Expenses | 12,169 | 9,330 | 7,296 | 5,946 | 6,239 | Upgrade
|
| Operating Income | -719.54 | -3,575 | -5,226 | -5,768 | -6,970 | Upgrade
|
| Interest Expense | -367.31 | -520.06 | -574.37 | -360.41 | -1,413 | Upgrade
|
| Interest & Investment Income | 926.51 | 634.82 | 574.31 | 200.41 | 138.66 | Upgrade
|
| Currency Exchange Gain (Loss) | -108.1 | 1,128 | 0.56 | 63.63 | 90.33 | Upgrade
|
| Other Non Operating Income (Expenses) | 24.61 | 5,074 | -2,429 | 268.61 | -8,494 | Upgrade
|
| EBT Excluding Unusual Items | -243.82 | 2,742 | -7,655 | -5,596 | -16,648 | Upgrade
|
| Gain (Loss) on Sale of Investments | -77.07 | 113.58 | 133.56 | -102.48 | -65.86 | Upgrade
|
| Gain (Loss) on Sale of Assets | 9.81 | 4.24 | - | 5.29 | 69.58 | Upgrade
|
| Asset Writedown | - | - | - | -38.72 | -0.8 | Upgrade
|
| Pretax Income | -311.08 | 2,860 | -7,522 | -5,732 | -16,645 | Upgrade
|
| Net Income | -311.08 | 2,860 | -7,522 | -5,732 | -16,645 | Upgrade
|
| Net Income to Common | -311.08 | 2,860 | -7,522 | -5,732 | -16,645 | Upgrade
|
| Shares Outstanding (Basic) | 8 | 7 | 6 | 6 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | 8 | 7 | 6 | 6 | 5 | Upgrade
|
| Shares Change (YoY) | 13.65% | 14.72% | 1.10% | 28.34% | 13.05% | Upgrade
|
| EPS (Basic) | -38.00 | 397.00 | -1198.00 | -923.00 | -3440.00 | Upgrade
|
| EPS (Diluted) | -38.00 | 397.00 | -1198.00 | -923.00 | -3440.00 | Upgrade
|
| Free Cash Flow | -1,902 | -1,640 | -4,225 | -8,403 | -6,101 | Upgrade
|
| Free Cash Flow Per Share | -232.28 | -227.68 | -672.87 | -1353.18 | -1260.87 | Upgrade
|
| Gross Margin | 69.49% | 60.31% | 42.38% | 6.35% | -32.25% | Upgrade
|
| Operating Margin | -4.37% | -37.46% | -107.05% | -206.37% | -307.42% | Upgrade
|
| Profit Margin | -1.89% | 29.97% | -154.06% | -205.07% | -734.13% | Upgrade
|
| Free Cash Flow Margin | -11.54% | -17.18% | -86.53% | -300.65% | -269.08% | Upgrade
|
| EBITDA | -201.04 | -3,082 | -4,759 | -5,305 | -6,537 | Upgrade
|
| EBITDA Margin | -1.22% | -32.30% | -97.48% | -189.79% | -288.30% | Upgrade
|
| D&A For EBITDA | 518.51 | 492.36 | 467.32 | 463.41 | 433.53 | Upgrade
|
| EBIT | -719.54 | -3,575 | -5,226 | -5,768 | -6,970 | Upgrade
|
| EBIT Margin | -4.37% | -37.46% | -107.05% | -206.37% | - | Upgrade
|
| Advertising Expenses | 114.55 | 171.98 | 196.9 | 59.64 | 76.25 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.